Vibalogics Manufactures Clinical Trial Material for Janssen COVID-19 Vaccine Candidate

Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, announced in a May 14, 2020 press release that it will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by the Janssen Pharmaceutical Companies of Johnson & Johnson. Vibalogics is contracted to manufacture multiple batches at its GMP-accredited facility in Cuxhaven, Germany.

“This has been a tremendous challenge for everyone at Vibalogics, but one which the entire team has embraced as an opportunity to use our experience and expertise in the global fight against COVID-19,” said Stefan Beyer, managing director and CEO of Vibalogic, in the press release.

The CDMO recently invested in new equipment to handle larger clinical batches, including a new filling line capable of filling and labelling more than 30,000 vials per batch. Vibalogics is set to establish a commercial facility in North America for oncolytic viruses, viral vectors for gene therapy approaches, and viral vector vaccines in the near future.

Source: Viablogics